STOCK TITAN

Penumbra (PEN) Stock News

PEN NYSE

Penumbra, Inc. develops thrombectomy technologies for medical conditions involving blood clots, including ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its product portfolio includes computer assisted vacuum thrombectomy and devices such as the Indigo System, Penumbra System Reperfusion Catheter, ACE Reperfusion Catheters, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and Artemis Neuro Evacuation Device.

Recurring company news covers financial results, capital-structure updates, investor conference presentations, and clinical evidence for CAVT in pulmonary embolism and other vascular applications. Updates also include material agreements, shareholder voting matters, governance disclosures, and regulatory or clinical developments tied to Penumbra's thrombectomy and neurovascular products.

Rhea-AI Summary

Penumbra (NYSE: PEN) reported third-quarter 2026 revenue of $410.1 million, up 15.6% from the same quarter a year earlier. Thrombectomy revenue rose 18.1% to $279.2 million, while embolization and access revenue increased 10.8% to $131.0 million. Gross margin reached 68.3%, versus 67.8% a year earlier.

Operating income increased to $50.739 million from $48.838 million, but net income fell to $42.279 million from $45.851 million. Diluted earnings per share declined to $1.07 from $1.17. Operating expenses rose to $229.564 million from $191.578 million, including $7.1 million in acquisition-related expenses. Penumbra said its pending acquisition by Boston Scientific (NYSE: BSX) is the reason it will not provide full-year 2026 guidance or host a quarterly results call. Nine-month revenue rose 15.4% to $1.175 billion, while net income fell to $109.674 million from $130.344 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
-
Rhea-AI Summary

Penumbra (PEN) received FDA clearance for its Lightning computer assisted vacuum thrombectomy technology to treat deep vein thrombosis, or DVT. The clearance is supported by BOLT-DVT, a prospective, multicenter trial enrolling patients with iliofemoral DVT. The technology removes blood clots using suction.

Complete or near-complete clot removal occurred in 98% of patients, with a median device time of 18 minutes. The 48-hour major adverse event rate was 3.1%; no device-related deaths or serious device-related adverse events were observed. Re-thrombosis occurred in 3.9% within 30 days. At 30 days, treated-vessel patency, meaning vessels remaining open, ranged from 88.8% to 96.3%, and 84.3% of patients had no post-thrombotic syndrome symptoms. Median leg pain fell from 5 at baseline to 0 immediately after treatment and at 30 days. Median VEINES-QOL quality-of-life scores improved from 49.3 to 84.2 at 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.60%
Tags
-
Rhea-AI Summary

Penumbra (PEN) announced STORM-PE subset results linking wearable-recorded daily activity with clinical walking performance in patients with pulmonary embolism.

Daily steps, walking-bout measures and peak 10-minute steps correlated significantly with 30-day 6-minute walk test performance. Correlations were strongest for time-matched measurements at 30 days and weaker with 90-day follow-up data. STORM-PE compared computer assisted vacuum thrombectomy (CAVT), a clot-removal procedure, plus anticoagulation with anticoagulation alone. Combination treatment showed better right ventricular recovery, greater walking improvement and more patients without physical limitations.

A separate STRIKE-PE interim analysis of 1,000 prospective patients reported one-year functional and quality-of-life benefits after CAVT, alongside short device times and low adverse events. STORM-PE was not powered to detect safety differences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
none
Rhea-AI Summary

Penumbra (NYSE: PEN) reported second-quarter 2026 revenue of $390.0 million, up 14.9% year over year. Thrombectomy revenue was $259.0 million (+12.5%), while embolization and access revenue reached $131.1 million (+20.0%). U.S. revenue grew 17.1% to $305.4 million; international revenue increased 7.6% to $84.6 million.

Gross margin was 67.9%, up 1.9 percentage points. Operating expenses were $223.9 million, including $6.9 million of acquisition-related costs tied to the pending acquisition by Boston Scientific (NYSE: BSX). Income from operations was $41.0 million, and net income was $34.8 million, or $0.88 diluted EPS. Penumbra will not provide 2026 guidance or host a Q2 earnings call due to the pending transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
-
Rhea-AI Summary

Penumbra (NYSE:PEN) reported top-line results from THUNDER, a U.S. Investigational Device Exemption study evaluating its THUNDERBOLT computer assisted vacuum thrombectomy (CAVT) system in acute ischemic stroke patients with emergent large vessel occlusion. The single-arm, prospective, multicenter trial enrolled 216 patients across 29 U.S. centers with core-lab adjudication.

THUNDER met its predefined performance goal, with 87.5% of cases achieving successful reperfusion (mTICI 2b-3). Post-THUNDERBOLT, 70.4% reached mTICI 2c-3, first-pass mTICI 2b-3 was 64.8%, median time-to-revascularization was 20 minutes, and complete clot ingestion was 83%. Device/procedure-related serious adverse events occurred in 2.8%, symptomatic intracranial hemorrhage in 0.9%, and 90-day all-cause mortality in 11.7%. Penumbra said THUNDERBOLT, the first and only CAVT device for stroke, has recently received U.S. FDA clearance and CE Mark.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
-
Rhea-AI Summary

Penumbra (NYSE:PEN) enrolled the first patient in FORWARD, an international, real‑world, prospective multi-center study evaluating mechanical thrombectomy, including computer assisted vacuum thrombectomy (CAVT) and modulated aspiration, for distal acute ischemic stroke.

The study will enroll up to 250 patients at about 40 sites and assess Penumbra’s RED reperfusion catheter portfolio, including the THUNDERBOLT CAVT platform, which has CE Mark and FDA clearance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
none
Rhea-AI Summary

Penumbra (NYSE:PEN) received CE Mark in Europe for its THUNDERBOLT computer assisted vacuum thrombectomy (CAVT) system for acute ischemic stroke, following recent FDA clearance in the U.S.

THUNDERBOLT, powered by the Penumbra ENGINE, introduces modulated aspiration and is described as the only CAVT device available for stroke treatment in Europe and the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
none
-
Rhea-AI Summary

Penumbra (NYSE:PEN) received U.S. FDA clearance for THUNDERBOLT, a computer assisted vacuum thrombectomy (CAVT) system for acute ischemic stroke. The platform delivers modulated aspiration to detect, fatigue and ingest clot at the occlusion, aiming for faster, more complete clot removal.

According to Penumbra, THUNDERBOLT is the first and only CAVT device cleared for stroke treatment in the U.S. and will be packaged with selected RED aspiration catheters.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
-
Rhea-AI Summary

Penumbra (NYSE: PEN) reported Q1 2026 revenue of $374.8 million, up 15.6% year-over-year, with thrombectomy revenue $253.9 million (+12.1%) and embolization & access $120.8 million (+23.8%). Gross margin was 67.6%. Operating expenses were $215.2 million (R&D $22.4M; SG&A $192.8M, including $9.4M acquisition-related expenses). Income from operations was $38.2 million and net income $32.6 million. Given the pending acquisition by Boston Scientific (NYSE: BSX), the company will not provide full-year 2026 guidance or host an earnings call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
Rhea-AI Summary

Penumbra (NYSE: PEN) reported 90-day STORM-PE randomized trial results showing computer assisted vacuum thrombectomy (CAVT) plus anticoagulation produced significantly better functional outcomes versus anticoagulation alone for intermediate-high risk pulmonary embolism.

Key results: 6-minute walk 479m vs 368m (P=0.003); 94% vs 75.2% predicted walk distance (P=0.022); NYHA Class I 97% vs 76% (P=0.022). Safety through 90 days was comparable with no device-related mortality.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
none

FAQ

What is the current stock price of Penumbra (PEN)?

Penumbra (PEN) last closed at $320.01.

What is the market cap of Penumbra (PEN)?

The market cap of Penumbra (PEN) is approximately $12.6B.